Design and Synthesis of 68Ga‐Labeled Peptide‐Based Heterodimers for Dual Targeting of NTS1 and GRPR
Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS1) and Gastrin‐Releasing Peptide Receptor (GRPR) are both G‐protei...
Uloženo v:
| Vydáno v: | ChemMedChem Ročník 20; číslo 9; s. e202400843 - n/a |
|---|---|
| Hlavní autoři: | , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
WEINHEIM
Wiley
05.05.2025
Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Témata: | |
| ISSN: | 1860-7179, 1860-7187, 1860-7187 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS1) and Gastrin‐Releasing Peptide Receptor (GRPR) are both G‐protein coupled receptors with complementary profile of expression in several cancer types. This work proposes the design, the synthesis and the in vitro radiopharmaceutical characterization of three heterodimers, based on GRP/NT modified peptides, radiolabeled with gallium‐68. Two NTS1/GRPR targeting pharmacophores containing linear hybrids that differ in the C‐terminus were synthesized (i. e., JMV 7110 and JMV 7253). The branched analogue of the silicon‐containing heterodimer JMV 7110, namely JMV 7266, was also synthesized. After radiolabeling with 68Ga, saturation binding studies performed on HT29 (NTS1+/GRPR−) and PC3 (NTS1+/GRPR+) cells demonstrated a significant loss in NTS1 and GRPR affinity compared to the reference monomers with the exception of the NTS1 affinity of [68Ga]Ga‐JMV 7266 which was preserved. Considering cellular processing, NTS1‐internalization at 1 h was the highest with [68Ga]Ga‐JMV 7266 and was similar to the reference compound. Interestingly [68Ga]Ga‐JMV 7266 demonstrated lower efflux than the other linear heterodimers but also than its NT reference compound. The branched structure of [68Ga]Ga‐JMV 7266 seems beneficial for dual NTS1/GRPR targeting.
Tumor heterogeneity is challenging for cancer diagnosis and treatment. This study designs and evaluates three gallium‐68 radiolabeled heterodimers targeting two G‐protein coupled receptors, namely NTS1 (neurotensin receptor 1) and GRPR (gastrin‐releasing‐peptide receptor). The branched analogue [68Ga]Ga‐JMV 7266 preserves NTS1 affinity, exhibits higher internalization and reduced efflux, highlighting its potential as a promising dual‐targeting agent for improved cancer imaging. |
|---|---|
| AbstractList | Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS1) and Gastrin-Releasing Peptide Receptor (GRPR) are both G-protein coupled receptors with complementary profile of expression in several cancer types. This work proposes the design, the synthesis and the in vitro radiopharmaceutical characterization of three heterodimers, based on GRP/NT modified peptides, radiolabeled with gallium-68. Two NTS1/GRPR targeting pharmacophores containing linear hybrids that differ in the C-terminus were synthesized (i. e., JMV 7110 and JMV 7253). The branched analogue of the silicon-containing heterodimer JMV 7110, namely JMV 7266, was also synthesized. After radiolabeling with 68Ga, saturation binding studies performed on HT29 (NTS1 +/GRPR-) and PC3 (NTS1 +/GRPR+) cells demonstrated a significant loss in NTS1 and GRPR affinity compared to the reference monomers with the exception of the NTS1 affinity of [68Ga]Ga-JMV 7266 which was preserved. Considering cellular processing, NTS1-internalization at 1 h was the highest with [68Ga]Ga-JMV 7266 and was similar to the reference compound. Interestingly [68Ga]Ga-JMV 7266 demonstrated lower efflux than the other linear heterodimers but also than its NT reference compound. The branched structure of [68Ga]Ga-JMV 7266 seems beneficial for dual NTS1/GRPR targeting.Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS1) and Gastrin-Releasing Peptide Receptor (GRPR) are both G-protein coupled receptors with complementary profile of expression in several cancer types. This work proposes the design, the synthesis and the in vitro radiopharmaceutical characterization of three heterodimers, based on GRP/NT modified peptides, radiolabeled with gallium-68. Two NTS1/GRPR targeting pharmacophores containing linear hybrids that differ in the C-terminus were synthesized (i. e., JMV 7110 and JMV 7253). The branched analogue of the silicon-containing heterodimer JMV 7110, namely JMV 7266, was also synthesized. After radiolabeling with 68Ga, saturation binding studies performed on HT29 (NTS1 +/GRPR-) and PC3 (NTS1 +/GRPR+) cells demonstrated a significant loss in NTS1 and GRPR affinity compared to the reference monomers with the exception of the NTS1 affinity of [68Ga]Ga-JMV 7266 which was preserved. Considering cellular processing, NTS1-internalization at 1 h was the highest with [68Ga]Ga-JMV 7266 and was similar to the reference compound. Interestingly [68Ga]Ga-JMV 7266 demonstrated lower efflux than the other linear heterodimers but also than its NT reference compound. The branched structure of [68Ga]Ga-JMV 7266 seems beneficial for dual NTS1/GRPR targeting. Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS1) and Gastrin‐Releasing Peptide Receptor (GRPR) are both G‐protein coupled receptors with complementary profile of expression in several cancer types. This work proposes the design, the synthesis and the in vitro radiopharmaceutical characterization of three heterodimers, based on GRP/NT modified peptides, radiolabeled with gallium‐68. Two NTS1/GRPR targeting pharmacophores containing linear hybrids that differ in the C‐terminus were synthesized (i. e., JMV 7110 and JMV 7253). The branched analogue of the silicon‐containing heterodimer JMV 7110, namely JMV 7266, was also synthesized. After radiolabeling with 68Ga, saturation binding studies performed on HT29 (NTS1+/GRPR−) and PC3 (NTS1+/GRPR+) cells demonstrated a significant loss in NTS1 and GRPR affinity compared to the reference monomers with the exception of the NTS1 affinity of [68Ga]Ga‐JMV 7266 which was preserved. Considering cellular processing, NTS1‐internalization at 1 h was the highest with [68Ga]Ga‐JMV 7266 and was similar to the reference compound. Interestingly [68Ga]Ga‐JMV 7266 demonstrated lower efflux than the other linear heterodimers but also than its NT reference compound. The branched structure of [68Ga]Ga‐JMV 7266 seems beneficial for dual NTS1/GRPR targeting. Tumor heterogeneity is challenging for cancer diagnosis and treatment. This study designs and evaluates three gallium‐68 radiolabeled heterodimers targeting two G‐protein coupled receptors, namely NTS1 (neurotensin receptor 1) and GRPR (gastrin‐releasing‐peptide receptor). The branched analogue [68Ga]Ga‐JMV 7266 preserves NTS1 affinity, exhibits higher internalization and reduced efflux, highlighting its potential as a promising dual‐targeting agent for improved cancer imaging. Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS1) and Gastrin‐Releasing Peptide Receptor (GRPR) are both G‐protein coupled receptors with complementary profile of expression in several cancer types. This work proposes the design, the synthesis and the in vitro radiopharmaceutical characterization of three heterodimers, based on GRP/NT modified peptides, radiolabeled with gallium‐68. Two NTS1/GRPR targeting pharmacophores containing linear hybrids that differ in the C‐terminus were synthesized (i. e., JMV 7110 and JMV 7253). The branched analogue of the silicon‐containing heterodimer JMV 7110, namely JMV 7266, was also synthesized. After radiolabeling with 68Ga, saturation binding studies performed on HT29 (NTS1+/GRPR−) and PC3 (NTS1+/GRPR+) cells demonstrated a significant loss in NTS1 and GRPR affinity compared to the reference monomers with the exception of the NTS1 affinity of [68Ga]Ga‐JMV 7266 which was preserved. Considering cellular processing, NTS1‐internalization at 1 h was the highest with [68Ga]Ga‐JMV 7266 and was similar to the reference compound. Interestingly [68Ga]Ga‐JMV 7266 demonstrated lower efflux than the other linear heterodimers but also than its NT reference compound. The branched structure of [68Ga]Ga‐JMV 7266 seems beneficial for dual NTS1/GRPR targeting. Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS1) and Gastrin‐Releasing Peptide Receptor (GRPR) are both G‐protein coupled receptors with complementary profile of expression in several cancer types. This work proposes the design, the synthesis and the in vitro radiopharmaceutical characterization of three heterodimers, based on GRP/NT modified peptides, radiolabeled with gallium‐68. Two NTS1/GRPR targeting pharmacophores containing linear hybrids that differ in the C‐terminus were synthesized (i. e., JMV 7110 and JMV 7253). The branched analogue of the silicon‐containing heterodimer JMV 7110, namely JMV 7266, was also synthesized. After radiolabeling with 68Ga, saturation binding studies performed on HT29 (NTS1 +/GRPR−) and PC3 (NTS1 +/GRPR+) cells demonstrated a significant loss in NTS1 and GRPR affinity compared to the reference monomers with the exception of the NTS1 affinity of [68Ga]Ga‐JMV 7266 which was preserved. Considering cellular processing, NTS1‐internalization at 1 h was the highest with [68Ga]Ga‐JMV 7266 and was similar to the reference compound. Interestingly [68Ga]Ga‐JMV 7266 demonstrated lower efflux than the other linear heterodimers but also than its NT reference compound. The branched structure of [68Ga]Ga‐JMV 7266 seems beneficial for dual NTS1/GRPR targeting. Tumor heterogeneity is challenging for cancer diagnosis and treatment. This study designs and evaluates three gallium‐68 radiolabeled heterodimers targeting two G‐protein coupled receptors, namely NTS1 (neurotensin receptor 1) and GRPR (gastrin‐releasing‐peptide receptor). The branched analogue [68Ga]Ga‐JMV 7266 preserves NTS1 affinity, exhibits higher internalization and reduced efflux, highlighting its potential as a promising dual‐targeting agent for improved cancer imaging. Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an appealing approach for improved diagnostic procedures. Neurotensin receptor 1 (NTS1) and Gastrin-Releasing Peptide Receptor (GRPR) are both G-protein coupled receptors with complementary profile of expression in several cancer types. This work proposes the design, the synthesis and the in vitro radiopharmaceutical characterization of three heterodimers, based on GRP/NT modified peptides, radiolabeled with gallium-68. Two NTS1/GRPR targeting pharmacophores containing linear hybrids that differ in the C-terminus were synthesized (i. e., JMV 7110 and JMV 7253). The branched analogue of the silicon-containing heterodimer JMV 7110, namely JMV 7266, was also synthesized. After radiolabeling with 68Ga, saturation binding studies performed on HT29 (NTS1+/GRPR-) and PC3 (NTS1+/GRPR+) cells demonstrated a significant loss in NTS1 and GRPR affinity compared to the reference monomers with the exception of the NTS1 affinity of [68Ga]Ga-JMV 7266 which was preserved. Considering cellular processing, NTS1-internalization at 1 h was the highest with [68Ga]Ga-JMV 7266 and was similar to the reference compound. Interestingly [68Ga]Ga-JMV 7266 demonstrated lower efflux than the other linear heterodimers but also than its NT reference compound. The branched structure of [68Ga]Ga-JMV 7266 seems beneficial for dual NTS1/GRPR targeting. |
| ArticleNumber | 202400843 |
| Author | Vimont, Delphine Hindié, Elif Cavelier, Florine Morgat, Clément Rémond, Emmanuelle Ait‐Arsa, Imade Bodin, Sacha Lamare, Frédéric Previti, Santo Jestin, Emmanuelle |
| AuthorAffiliation | 2 CHU Bordeaux Department of Nuclear Medicine F-33000 Bordeaux France 1 University of Bordeaux CNRS EPHE INCIA UMR 5287 F-33400 Talence France 3 Pôle Chime Balard IBMM UMR 5247 CNRS Université Montpellier ENSCM F-34293 Montpellier France 6 Institut Universitaire de France IUF F-75000 Paris France 5 GIP CYROI – Cyclotron Réunion Océan Indien F-97490 Saint Clotilde France 4 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences University of Messina Viale Stagno d'Alcontres 31 98166 Messina Italy |
| AuthorAffiliation_xml | – name: 3 Pôle Chime Balard IBMM UMR 5247 CNRS Université Montpellier ENSCM F-34293 Montpellier France – name: 2 CHU Bordeaux Department of Nuclear Medicine F-33000 Bordeaux France – name: 1 University of Bordeaux CNRS EPHE INCIA UMR 5287 F-33400 Talence France – name: 4 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences University of Messina Viale Stagno d'Alcontres 31 98166 Messina Italy – name: 5 GIP CYROI – Cyclotron Réunion Océan Indien F-97490 Saint Clotilde France – name: 6 Institut Universitaire de France IUF F-75000 Paris France |
| Author_xml | – sequence: 1 givenname: Sacha orcidid: 0000-0001-7331-8536 surname: Bodin fullname: Bodin, Sacha organization: CHU Bordeaux – sequence: 2 givenname: Santo surname: Previti fullname: Previti, Santo organization: University of Messina – sequence: 3 givenname: Emmanuelle surname: Jestin fullname: Jestin, Emmanuelle organization: GIP CYROI – Cyclotron Réunion Océan Indien – sequence: 4 givenname: Emmanuelle surname: Rémond fullname: Rémond, Emmanuelle organization: ENSCM – sequence: 5 givenname: Delphine surname: Vimont fullname: Vimont, Delphine organization: INCIA UMR 5287 – sequence: 6 givenname: Frédéric surname: Lamare fullname: Lamare, Frédéric organization: CHU Bordeaux – sequence: 7 givenname: Imade surname: Ait‐Arsa fullname: Ait‐Arsa, Imade organization: GIP CYROI – Cyclotron Réunion Océan Indien – sequence: 8 givenname: Elif surname: Hindié fullname: Hindié, Elif organization: IUF – sequence: 9 givenname: Florine orcidid: 0000-0001-5308-6416 surname: Cavelier fullname: Cavelier, Florine email: florine.cavelier@umontpellier.fr organization: ENSCM – sequence: 10 givenname: Clément orcidid: 0000-0002-9432-9223 surname: Morgat fullname: Morgat, Clément organization: CHU Bordeaux |
| BookMark | eNqNkstu1DAUhi1URC-wZR2JDRKacnxJ4qwQZMoUaYCqHdaWE5-krhJ7Gieg2fUReEaeBA8dRYIV3ti_z3c-2dI5JUfOOyTkJYVzCsDe1r2pzxkwASAFf0JOqMxgkVOZH83nvDgmpyHcAQghqXxGjnlRgIQMTki7xGBbl2hnkpudG29jDIlvkkyu9K-Hn2tdYYcmucLtaA3Gmw86xHyJIw7e2B6HkDR-SJaT7pKNHlocrWv3hi-bG_rHu7q-un5Onja6C_jisJ-Rbx8vNuXlYv119al8v15sWcH4QgPFpuI6w6xGntZFkZlGapGnoCtgJs1MqqHRYFIhpZHcQM6MKKjUsSI4PyPvHr3bqerR1OjGQXdqO9heDzvltVV_V5y9Va3_riiDVDIhouH1wTD4-wnDqHobauw67dBPQXGa8ZRCDiyir_5B7_w0uPg_xRmTkrGc7YXykfqBlW9CbdHVOL8IgArGocgZxEVLO-rRelf6yY2x9c3_t0a6ONC2w92MUVD7UVH7UVHzqKjy87KcE_8NxWCzTg |
| Cites_doi | 10.2967/jnumed.122.263889 10.1007/s00726-013-1492-2 10.1186/s13550-019-0517-6 10.1002/jlcr.3162 10.3389/fchem.2020.00406 10.1016/j.peptides.2006.04.030 10.1371/journal.pone.0210905 10.1038/srep38564 10.1002/anie.202007920 10.1016/j.peptides.2007.06.030 10.1371/journal.pone.0004223 10.1002/psc.3471 10.1056/NEJMoa1607427 10.3390/cancers13225766 10.1021/bc1004284 10.1039/d4md00491d 10.3390/cancers15082345 10.1007/s10549-021-06402-5 10.2967/jnumed.114.142000 10.1021/acs.bioconjchem.0c00419 10.3390/ijms20071721 10.3390/pharmaceutics13081160 10.1016/j.peptides.2008.04.014 10.1016/j.bbcan.2006.01.003 10.1007/s10585-009-9265-8 10.1016/j.bbr.2021.113189 10.1016/j.trecan.2020.01.010 10.1021/acs.jmedchem.5b00841 10.1021/acsomega.2c07814 10.1007/s00259-010-1445-x 10.2967/jnumed.116.188011 10.1038/nrclinonc.2017.166 |
| ContentType | Journal Article |
| Copyright | 2025 The Authors. ChemMedChem published by Wiley-VCH GmbH 2025. This work is published under Creative Commons Attribution License~https://creativecommons.org/licenses/by/3.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2025 The Authors. ChemMedChem published by Wiley-VCH GmbH. |
| Copyright_xml | – notice: 2025 The Authors. ChemMedChem published by Wiley-VCH GmbH – notice: 2025. This work is published under Creative Commons Attribution License~https://creativecommons.org/licenses/by/3.0/ (the "License"). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2025 The Authors. ChemMedChem published by Wiley-VCH GmbH. |
| DBID | 24P 17B 1KM ACAAO BLEPL DTL EGQ 7QO 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 5PM |
| DOI | 10.1002/cmdc.202400843 |
| DatabaseName | Wiley Online Library Open Access Web of Knowledge Index Chemicus Web of Science - Science Citation Index Expanded - 2025 Web of Science Core Collection Science Citation Index Expanded Web of Science Primary (SCIE, SSCI & AHCI) Biotechnology Research Abstracts Neurosciences Abstracts Toxicology Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | Web of Science Genetics Abstracts Biotechnology Research Abstracts Technology Research Database Toxicology Abstracts ProQuest Health & Medical Complete (Alumni) Engineering Research Database Neurosciences Abstracts Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Genetics Abstracts Web of Science |
| Database_xml | – sequence: 1 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: 1KM name: Index Chemicus url: https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC sourceTypes: Enrichment Source Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1860-7187 |
| EndPage | n/a |
| ExternalDocumentID | PMC12058244 001423097200001 CMDC202400843 |
| Genre | article |
| GrantInformation_xml | – fundername: RRI NEWMOON Impulsion of Bordeaux University |
| GroupedDBID | --- 05W 0R~ 1L6 1OC 24P 29B 33P 3WU 4.4 53G 5GY 66C 6J9 77Q 8-0 8-1 AAESR AAHHS AAHQN AAMNL AANLZ AAXRX AAYCA AAZKR ABCUV ABIJN ABJNI ABLJU ACAHQ ACCFJ ACCZN ACGFS ACIWK ACPOU ACPRK ACXBN ACXQS ADBBV ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AENEX AEQDE AEUYR AEYWJ AFBPY AFFPM AFGKR AFRAH AFWVQ AGHNM AGYGG AHBTC AHMBA AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMYDB AZVAB BDRZF BFHJK BMXJE BRXPI CS3 DCZOG DR2 DRFUL DRSTM DU5 EBS F5P G-S HBH HGLYW HHZ HZ~ IX1 LATKE LAW LEEKS LITHE LOXES LUTES LYRES MEWTI MXFUL MXSTM MY~ O9- OIG P2W PQQKQ ROL SUPJJ W99 WBKPD WOHZO WXSBR XV2 YZZ ZZTAW ~S- 17B 1KM AAMMB AEFGJ AGXDD AIDQK AIDYY BLEPL DTL GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED GROUPED_WOS_WEB_OF_SCIENCE LH4 7QO 7TK 7U7 8FD C1K FR3 K9. P64 RC3 7X8 5PM |
| ID | FETCH-LOGICAL-p2923-a01efb3a6e6ce35c996df8a4750ab02d56d5a0fa0d5488d83d072d4918a6d5433 |
| IEDL.DBID | 24P |
| ISICitedReferencesCount | 2 |
| ISICitedReferencesURI | https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=001423097200001 |
| ISSN | 1860-7179 1860-7187 |
| IngestDate | Tue Nov 04 02:04:17 EST 2025 Sun Nov 09 12:45:52 EST 2025 Sat Nov 29 14:20:33 EST 2025 Fri Dec 05 22:55:15 EST 2025 Mon Oct 27 23:23:44 EDT 2025 Thu May 08 09:30:20 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | NTS1 PSMA Bombesin ANTAGONIST PET imaging Heterodimers RECEPTOR Neurotensin GASTRIN-RELEASING-PEPTIDE GRPR PRIMARY PROSTATE-CANCER EXPRESSION |
| Language | English |
| License | Attribution This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| LogoURL | https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg |
| MergedId | FETCHMERGED-LOGICAL-p2923-a01efb3a6e6ce35c996df8a4750ab02d56d5a0fa0d5488d83d072d4918a6d5433 |
| Notes | These authors contributed equally. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0002-9432-9223 0000-0001-7331-8536 0000-0001-5308-6416 |
| OpenAccessLink | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcmdc.202400843 |
| PMID | 39908060 |
| PQID | 3228822724 |
| PQPubID | 986335 |
| PageCount | 9 |
| ParticipantIDs | proquest_miscellaneous_3163510702 wiley_primary_10_1002_cmdc_202400843_CMDC202400843 proquest_journals_3228822724 webofscience_primary_001423097200001CitationCount pubmedcentral_primary_oai_pubmedcentral_nih_gov_12058244 webofscience_primary_001423097200001 |
| PublicationCentury | 2000 |
| PublicationDate | May 5, 2025 |
| PublicationDateYYYYMMDD | 2025-05-05 |
| PublicationDate_xml | – month: 05 year: 2025 text: May 5, 2025 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | WEINHEIM |
| PublicationPlace_xml | – name: WEINHEIM – name: Weinheim – name: Hoboken |
| PublicationTitle | ChemMedChem |
| PublicationTitleAbbrev | CHEMMEDCHEM |
| PublicationYear | 2025 |
| Publisher | Wiley Wiley Subscription Services, Inc John Wiley and Sons Inc |
| Publisher_xml | – name: Wiley – name: Wiley Subscription Services, Inc – name: John Wiley and Sons Inc |
| References | 2019; 9 2015; 58 2010; 37 2023; 15 2013; 45 2023; 8 2021; 405 1981; 24 2006; 1766 2020; 59 2017; 376 2009; 26 2007; 28 2023; 64 2020; 8 2021; 13 2020; 6 2016; 6 2020; 31 2017; 58 2023; 29 2006; 27 2008; 29 2011; 22 2014; 57 1999; 53 1999; 276 2009; 4 2018; 15 2014; 55 2021; 190 Vivancos, M (WOS:000672567100011) 2021; 405 Wang, WH (WOS:000559988700001) 2020; 59 Mansi, R (WOS:000727338400001) 2021; 13 Khatib, S (WOS:000530164900004) 2020; 6 Dagogo-Jack, I (WOS:000422916700016) 2018; 15 Schollhammer, R (WOS:000984068000001) 2023; 15 Bodin, S (WOS:000937046700001) 2023 Carraway, RE (WOS:000241202400008) 2006; 27 Fanelli, R (WOS:000362701600013) 2015; 58 STPIERRE, S (WOS:A1981LH29100004) 1981; 24 Bossard, C (WOS:000250326100014) 2007; 28 Previti, S (WOS:000910090900001) 2023; 29 Schollhammer, R (WOS:000470138800002) 2019; 9 Reubi, JC (WOS:000280639400014) 2010; 37 Morgat, C (WOS:000408907200013) 2017; 58 Patel, O (WOS:000240243800002) 2006; 1766 Josan, JS (WOS:000292893100004) 2011; 22 Previti, S (WOS:001325812600001) 2024; 15 Morgat, C (WOS:000455810200061) 2019; 14 Krumm, BE (WOS:000389527400001) 2016; 6 Previti, S (WOS:000543035600001) 2020; 8 Morgat, C (WOS:000342712600024) 2014; 55 René, A (WOS:000321947700009) 2013; 45 Dupouy, S (WOS:000265481900005) 2009; 4 Schollhammer, R (WOS:000975392000010) 2023; 64 Carroll, RE (WOS:000079055700013) 1999; 276 Strosberg, J (WOS:000392198400007) 2017; 376 Llinares, M (WOS:000079876600006) 1999; 53 Rivera, CA (WOS:000271722300007) 2009; 26 Morgat, C (WOS:000702574400001) 2021; 190 Valverde, IE (WOS:000334540800014) 2014; 57 Morgat, C (WOS:000464989100001) 2019; 20 Chastel, A (WOS:000689990100001) 2021; 13 Fanelli, R (WOS:000584490900009) 2020; 31 Gui, XY (WOS:000259346400020) 2008; 29 |
| References_xml | – volume: 4 year: 2009 publication-title: PLoS One – volume: 26 start-page: 663 year: 2009 end-page: 671 publication-title: Clin. Exp. Metastasis – volume: 55 start-page: 1650 year: 2014 end-page: 1657 publication-title: J. Nucl. Med. – volume: 22 start-page: 1270 year: 2011 end-page: 1278 publication-title: Bioconjugate Chem. – volume: 58 start-page: 1401 year: 2017 end-page: 1407 publication-title: J. Nucl. Med. – volume: 64 start-page: 379 year: 2023 end-page: 385 publication-title: J. Nucl. Med. – volume: 37 start-page: 1551 year: 2010 end-page: 1558 publication-title: Eur. J. Nucl. Med. Mol. Imaging – volume: 8 start-page: 6994 year: 2023 end-page: 7004 publication-title: ACS Omega – volume: 31 start-page: 2339 year: 2020 end-page: 2349 publication-title: Bioconjugate Chem. – volume: 29 year: 2023 publication-title: J. Pept. Sci. – volume: 24 start-page: 370 year: 1981 end-page: 376 publication-title: J. Med. Chem. – volume: 6 start-page: 38564 year: 2016 publication-title: Sci. Rep. – volume: 405 year: 2021 publication-title: Behav. Brain Res. – volume: 9 start-page: 52 year: 2019 publication-title: EJNMMI Res. – volume: 57 start-page: 275 year: 2014 end-page: 278 publication-title: J. Labelled Compd. Radiopharm. – volume: 276 start-page: G655 year: 1999 end-page: 665 publication-title: Am. J. Physiol. – volume: 59 start-page: 17897 year: 2020 end-page: 17902 publication-title: Angew. Chem. Int. Ed. Engl. – volume: 29 start-page: 1609 year: 2008 end-page: 1615 publication-title: Peptides – volume: 6 start-page: 267 year: 2020 end-page: 271 publication-title: Trends Cancer – volume: 15 start-page: 81 year: 2018 end-page: 94 publication-title: Nat. Rev. Clin. Oncol. – volume: 13 start-page: 1160 year: 2021 publication-title: Pharmaceutica – volume: 15 start-page: 2345 year: 2023 publication-title: Cancers – volume: 53 start-page: 275 year: 1999 end-page: 283 publication-title: J. Pept. Res. – volume: 45 start-page: 301 year: 2013 end-page: 307 publication-title: Amino Acids – volume: 190 start-page: 403 year: 2021 end-page: 413 publication-title: Breast Cancer Res. Treat. – volume: 28 start-page: 2030 year: 2007 end-page: 2035 publication-title: Peptides – volume: 8 start-page: 406 year: 2020 publication-title: Front. Chem. – volume: 58 start-page: 7785 year: 2015 end-page: 7795 publication-title: J. Med. Chem. – volume: 27 start-page: 2445 year: 2006 end-page: 2460 publication-title: Peptides – volume: 13 start-page: 5766 year: 2021 publication-title: Cancers (Basel). – volume: 1766 start-page: 23 year: 2006 end-page: 41 publication-title: Biochim. Biophys. Acta – volume: 376 start-page: 125 year: 2017 end-page: 135 publication-title: N. Engl. J. Med. – volume: 64 start-page: 379 year: 2023 ident: WOS:000975392000010 article-title: Comparison of 68Ga-PSMA-617 PET/CT and 68Ga-RM2 PET/CT in Patients with Localized Prostate Cancer Who Are Candidates for Radical Prostatectomy: A Prospective, Single-Arm, Single-Center, Phase II Study publication-title: JOURNAL OF NUCLEAR MEDICINE doi: 10.2967/jnumed.122.263889 – volume: 45 start-page: 301 year: 2013 ident: WOS:000321947700009 article-title: (L)-(Trimethylsilyl)alanine synthesis exploiting hydroxypinanone-induced diastereoselective alkylation publication-title: AMINO ACIDS doi: 10.1007/s00726-013-1492-2 – volume: 9 start-page: ARTN 52 year: 2019 ident: WOS:000470138800002 article-title: Comparison of the radiolabeled PSMA-inhibitor 111In-PSMA-617 and the radiolabeled GRP-R antagonist 111In-RM2 in primary prostate cancer samples publication-title: EJNMMI RESEARCH doi: 10.1186/s13550-019-0517-6 – volume: 57 start-page: 275 year: 2014 ident: WOS:000334540800014 article-title: Radiolabeled antagonistic bombesin peptidomimetics for tumor targeting publication-title: JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS doi: 10.1002/jlcr.3162 – volume: 8 start-page: ARTN 406 year: 2020 ident: WOS:000543035600001 article-title: Insightful Backbone Modifications Preventing Proteolytic Degradation of Neurotensin Analogs Improve NTS1-Induced Protective Hypothermia publication-title: FRONTIERS IN CHEMISTRY doi: 10.3389/fchem.2020.00406 – volume: 27 start-page: 2445 year: 2006 ident: WOS:000241202400008 article-title: Involvement of neurotensin in cancer growth: Evidence, mechanisms and development of diagnostic tools publication-title: PEPTIDES doi: 10.1016/j.peptides.2006.04.030 – volume: 14 start-page: ARTN e0210905 year: 2019 ident: WOS:000455810200061 article-title: Comparison of the binding of the gastrin-releasing peptide receptor (GRP-R) antagonist 68Ga-RM2 and 18F-FDG in breast cancer samples publication-title: PLOS ONE doi: 10.1371/journal.pone.0210905 – volume: 6 start-page: ARTN 38564 year: 2016 ident: WOS:000389527400001 article-title: Structure and dynamics of a constitutively active neurotensin receptor publication-title: SCIENTIFIC REPORTS doi: 10.1038/srep38564 – volume: 59 start-page: 17897 year: 2020 ident: WOS:000559988700001 article-title: Peptide-Conjugated Long-Lived Theranostic Imaging for Targeting GRPr in Cancer and Immune Cells publication-title: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION doi: 10.1002/anie.202007920 – volume: 28 start-page: 2030 year: 2007 ident: WOS:000250326100014 article-title: Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear β-catenin in inflammatory bowel disease-related oncogenesis publication-title: PEPTIDES doi: 10.1016/j.peptides.2007.06.030 – volume: 4 start-page: ARTN e4223 year: 2009 ident: WOS:000265481900005 article-title: The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression publication-title: PLOS ONE doi: 10.1371/journal.pone.0004223 – volume: 29 year: 2023 ident: WOS:000910090900001 article-title: Opening the amino acid toolbox for peptide-based NTS2-selective ligands as promising lead compounds for pain management publication-title: JOURNAL OF PEPTIDE SCIENCE doi: 10.1002/psc.3471 – volume: 376 start-page: 125 year: 2017 ident: WOS:000392198400007 article-title: Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors publication-title: NEW ENGLAND JOURNAL OF MEDICINE doi: 10.1056/NEJMoa1607427 – volume: 13 start-page: ARTN 5766 year: 2021 ident: WOS:000727338400001 article-title: Radiolabeled Bombesin Analogs publication-title: CANCERS doi: 10.3390/cancers13225766 – volume: 22 start-page: 1270 year: 2011 ident: WOS:000292893100004 article-title: Cell-Specific Targeting by Heterobivalent Ligands publication-title: BIOCONJUGATE CHEMISTRY doi: 10.1021/bc1004284 – volume: 15 start-page: 4153 year: 2024 ident: WOS:001325812600001 article-title: Rational design of NT-PSMA heterobivalent probes for prostate cancer theranostics publication-title: RSC MEDICINAL CHEMISTRY doi: 10.1039/d4md00491d – volume: 15 start-page: ARTN 2345 year: 2023 ident: WOS:000984068000001 article-title: Theranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R publication-title: CANCERS doi: 10.3390/cancers15082345 – volume: 190 start-page: 403 year: 2021 ident: WOS:000702574400001 article-title: Expression of neurotensin receptor-1 (NTS1) in primary breast tumors, cellular distribution, and association with clinical and biological factors publication-title: BREAST CANCER RESEARCH AND TREATMENT doi: 10.1007/s10549-021-06402-5 – volume: 55 start-page: 1650 year: 2014 ident: WOS:000342712600024 article-title: Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors publication-title: JOURNAL OF NUCLEAR MEDICINE doi: 10.2967/jnumed.114.142000 – volume: 31 start-page: 2339 year: 2020 ident: WOS:000584490900009 article-title: Silicon-Containing Neurotensin Analogues as Radiopharmaceuticals for NTS1-Positive Tumors Imaging publication-title: BIOCONJUGATE CHEMISTRY doi: 10.1021/acs.bioconjchem.0c00419 – volume: 276 start-page: G655 year: 1999 ident: WOS:000079055700013 article-title: Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans publication-title: AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY – volume: 24 start-page: 370 year: 1981 ident: WOS:A1981LH29100004 article-title: SYNTHESIS OF PEPTIDES BY THE SOLID-PHASE METHOD .6. NEUROTENSIN, FRAGMENTS, AND ANALOGS publication-title: JOURNAL OF MEDICINAL CHEMISTRY – volume: 20 start-page: ARTN 1721 year: 2019 ident: WOS:000464989100001 article-title: Neurotensin Receptor-1 Expression in Human Prostate Cancer: A Pilot Study on Primary Tumors and Lymph Node Metastases publication-title: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES doi: 10.3390/ijms20071721 – volume: 13 start-page: ARTN 1160 year: 2021 ident: WOS:000689990100001 article-title: 68Ga-Radiolabeling and Pharmacological Characterization of a Kit-Based Formulation of the Gastrin-Releasing Peptide Receptor (GRP-R) Antagonist RM2 for Convenient Preparation of [68Ga]Ga-RM2 publication-title: PHARMACEUTICS doi: 10.3390/pharmaceutics13081160 – volume: 29 start-page: 1609 year: 2008 ident: WOS:000259346400020 article-title: Increased neurotensin receptor-1 expression during progression of colonic adenocarcinoma publication-title: PEPTIDES doi: 10.1016/j.peptides.2008.04.014 – volume: 1766 start-page: 23 year: 2006 ident: WOS:000240243800002 article-title: Gastrin-releasing peptide and cancer publication-title: BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER doi: 10.1016/j.bbcan.2006.01.003 – volume: 26 start-page: 663 year: 2009 ident: WOS:000271722300007 article-title: Expression of GRP and its receptor is associated with improved survival in patients with colon cancer publication-title: CLINICAL & EXPERIMENTAL METASTASIS doi: 10.1007/s10585-009-9265-8 – volume: 405 start-page: ARTN 113189 year: 2021 ident: WOS:000672567100011 article-title: Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia publication-title: BEHAVIOURAL BRAIN RESEARCH doi: 10.1016/j.bbr.2021.113189 – volume: 6 start-page: 267 year: 2020 ident: WOS:000530164900004 article-title: Understanding the Cause and Consequence of Tumor Heterogeneity publication-title: TRENDS IN CANCER doi: 10.1016/j.trecan.2020.01.010 – volume: 58 start-page: 7785 year: 2015 ident: WOS:000362701600013 article-title: Synthesis and Characterization in Vitro and in Vivo of (L)-(Trimethylsilyl)alanine Containing Neurotensin Analogues publication-title: JOURNAL OF MEDICINAL CHEMISTRY doi: 10.1021/acs.jmedchem.5b00841 – year: 2023 ident: WOS:000937046700001 article-title: Design, Synthesis, and Biological Evaluation of the First Radio-Metalated Neurotensin Analogue Targeting Neurotensin Receptor 2 publication-title: ACS OMEGA doi: 10.1021/acsomega.2c07814 – volume: 37 start-page: 1551 year: 2010 ident: WOS:000280639400014 article-title: Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog publication-title: EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING doi: 10.1007/s00259-010-1445-x – volume: 58 start-page: 1401 year: 2017 ident: WOS:000408907200013 article-title: Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors publication-title: JOURNAL OF NUCLEAR MEDICINE doi: 10.2967/jnumed.116.188011 – volume: 53 start-page: 275 year: 1999 ident: WOS:000079876600006 article-title: Syntheses and biological activities of potent bombesin receptor antagonists publication-title: JOURNAL OF PEPTIDE RESEARCH – volume: 15 start-page: 81 year: 2018 ident: WOS:000422916700016 article-title: Tumour heterogeneity and resistance to cancer therapies publication-title: NATURE REVIEWS CLINICAL ONCOLOGY doi: 10.1038/nrclinonc.2017.166 |
| SSID | ssj0044818 |
| Score | 2.4255068 |
| Snippet | Tumor heterogeneity remains one of the main obstacles for cancer diagnosis and treatment. The simultaneous targeting of several cancer biomarkers is an... |
| Source | Web of Science |
| SourceID | pubmedcentral proquest webofscience wiley |
| SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | e202400843 |
| SubjectTerms | Affinity Biomarkers Bombesin Cancer Chemistry, Medicinal Efflux Gallium Gallium isotopes Gastrin GRPR Heterodimers Heterogeneity Hybrids Internalization Life Sciences & Biomedicine Neurotensin NTS1 Peptides PET imaging Pharmaceuticals Pharmacology & Pharmacy Pharmacophores Radiochemistry Radioisotopes Radiolabelling Receptors Science & Technology Synthesis |
| Title | Design and Synthesis of 68Ga‐Labeled Peptide‐Based Heterodimers for Dual Targeting of NTS1 and GRPR |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcmdc.202400843 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=001423097200001 https://www.proquest.com/docview/3228822724 https://www.proquest.com/docview/3163510702 https://pubmed.ncbi.nlm.nih.gov/PMC12058244 |
| Volume | 20 |
| WOS | 001423097200001 |
| WOSCitedRecordID | wos001423097200001 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1860-7187 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0044818 issn: 1860-7179 databaseCode: DRFUL dateStart: 20060101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Nb9MwGH4FGwcufCMyxmSkaadFsx0ndo7Q0u0wqqjrpN4iJ3ZGD6TT0k7qjZ_Ab-SX8Npp00XigOASKf5SIr8fz2u_fgxwLEshKhqZUBtahuihbag5rUImS2lFpd3pR3_ZhByP1WyWZg9O8bf8EN2Cm9MMb6-dguuiOduRhpbfjaMgdDmQSkSPYZ-xSLnLG7jItrYYYw-_wsdUQkMMXNItbSPlZ_3-PYD5p_TIziX1Uax3Q6Pn__8DL-DZBoKST63MvIRHtn4FJ1nLYb0-JdPdkazmlJyQbMduvX4NN0Of80F0bcjVukb82MwbsqhIos71rx8_L3WBnsyQzKXLGIsln9FRGnLh8m4WZu7WyQkiZTJc4UdMfSI6uk83wnh6xfy455Ns8gauR1-mg4twc1tDeMsRJYaaMlsVkU5sUtooLjGQMpXSAiGJLig3cWJiTStNDQZJyqjIUMmNSJnSWCOi6C3s1YvavgOCoCMtscTGqRGcpkUhksQZYsEqw2MdwOF2svKNyjU5WiaMFrjkIoCPXTUqi9sB0bVdrLANok80QpLyAFRvkvPbltwjd3Tb_Zp6_s3TbjNOY4VoKIDjh_LQ9XTRJgZ0qeR-yyQA9jfNBhsqdkdBsAyAe4npGrek0jx3spJ3spIPvg4H3dvBv3R6D0-5u8nYpW7Gh7C3vFvZD_CkvF_Om7sjr0T4lDN1BPvDyej68jd9myFo |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwEB5BQYILb0SggJGqnhrVcZzEOcIu7SK2q6gNUm-REzuwB7JVdxdpb_wEfiO_hBknmyUSB4Q4xo8okefxzXj8GeAgqaSseWh8bXjlo4e2vha89oOkSqysNZ1-dJdNJLOZurxMs66akM7CtPwQfcKNNMPZa1JwSkgf71hDq6-GOAipCFLJ8CbckuhqSNSFzLbGGIMPl-ILVMx9jFzSLW8jF8fD-QOE-af6yN4nDWGs80Mn9__DHzyAex0IZW9bqXkIN2zzCA6zlsV6c8Ty3aGs5RE7ZNmO33rzGD6PXdUH041hF5sGEeRyvmSLmsXqVP_8_mOqS_RlhmVUMGMstrxDV2nYhCpvFmZOmXKGWJmN1_gRuStFRwdKb5jlF4F77-l5dv4EPp28z0cTv7uvwb8SiBN9zQNbl6GObVzZMKowlDK10hJBiS65MFFsIs1rzQ2GScqo0PBEGJkGSmOPDMOnsNcsGvsMGMKOtMIWG6VGCp6WpYxjMsUyqI2ItAf729UqOqVbFmibMF4QiZAevOm7UV1oD0Q3drHGMYg_0QwlXHigBqtcXLX0HgURbg97mvkXR7wdCB4pxEMeHPwuEP1MijcxpEsT4TZNPAj-ZtioI2MnEoKVB8KJTD-4pZUWBclK0ctKMTobj_qn5_8y6TXcmeRn02L6YfbxBdwVdK8xFXJG-7C3ul7bl3C7-raaL69fOY36BdOuIss |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Pb9MwFH-CDiEujH8TgQFGmnZaNMdxEue4NXRDlCrqOmm3yIkd6IG0Wlqk3vgIfEY-yZ6dNCUSB4Q4xnasRH5_fs9-_j2Ao6jgvKS-cqWihYseWruS0dL1oiLSvJTm9qMtNhFNJuLmJk7bbEJzF6bhh-g23IxmWHttFFwvVXm6Yw0tvinDQWiSIAX378MeN5VkBrCXTEfX4605xvDDbvJ5IqQuxi7xlrmRstP-DD2M-acMyc4r9YGs9USj_f_wD0_gcQtDyVkjN0_hnq6ewXHa8FhvTshsdy2rPiHHJN0xXG-ew5fE5n0QWSlytakQQ9bzmixKEooL-evHz7HM0ZspkpqUGaWx5RydpSKXJvdmoeZmr5wgWibJGj9iZpPR0YWaGSazK8_OezFNpy_gevRhNrx024oN7pIhUnQl9XSZ-zLUYaH9oMBgSpVCcoQlMqdMBaEKJC0lVRgoCSV8RSOmeOwJiT3c9w9gUC0q_RIIAo-4wBYdxIozGuc5D0NjjLlXKhZIBw63q5W1aldnaJ0wYmAR4w6877pRYcwpiKz0Yo1jEIGiIYooc0D0VjlbNgQfmaHc7vdU86-WettjNBCIiBw4-l0gujdNxIlBXRwxe2zigPc3w4YtHbuhIVg5wKzIdIMbYmmWGVnJOlnJhp-TYff06l9eegcP02SUjT9OPr2GR8wUNjaZnMEhDFa3a_0GHhTfV_P69m2rUnd2PSPh |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Design+and+Synthesis+of+68Ga%E2%80%90Labeled+Peptide%E2%80%90Based+Heterodimers+for+Dual+Targeting+of+NTS1+and+GRPR&rft.jtitle=ChemMedChem&rft.au=Bodin%2C+Sacha&rft.au=Previti%2C+Santo&rft.au=Jestin%2C+Emmanuelle&rft.au=R%C3%A9mond%2C+Emmanuelle&rft.date=2025-05-05&rft.pub=John+Wiley+and+Sons+Inc&rft.issn=1860-7179&rft.eissn=1860-7187&rft.volume=20&rft.issue=9&rft_id=info:doi/10.1002%2Fcmdc.202400843&rft_id=info%3Apmid%2F39908060&rft.externalDocID=PMC12058244 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1860-7179&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1860-7179&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1860-7179&client=summon |